Anat  Ashkenazi net worth and biography

Anat Ashkenazi Biography and Net Worth

Sr. VP & CFO of Eli Lilly and Company

Anat Ashkenazi is senior vice president and chief financial officer for Eli Lilly and Company.

Since joining Lilly in 2001, Anat has held a range of roles across strategy, finance and Six Sigma. Most recently, she served as senior vice president, controller and CFO of Lilly Research Laboratories. In this role, she oversaw the CFOs of the company’s commercial businesses, as well as those for research and development, manufacturing and quality, and G&A functions. She also led the corporate strategic planning team, business transformation office, and served as CFO for several of the company’s global business areas. Prior to joining Lilly, she worked in financial services at Ma’alot Standard & Poor’s and at Ha'poalim Bank in Israel. 

Anat earned a bachelor’s degree from the Hebrew University in finance and economics and a Master of Business Administration from Tel Aviv University.

Anat currently serves on the board of directors at Maravai Life Sciences. She previously served on the board of directors for Varian Medical Systems, a market leader in radiation therapy.

How old is Anat Ashkenazi?

Ms. Ashkenazi is currently 51 years old. There are 8 older executives and no younger executives at Eli Lilly and Company. The oldest executive at Eli Lilly and Company is Mr. Jeffrey N. Simmons, Senior VP & President of Elanco Animal Health, who is 57 years old. Learn More on Anat Ashkenazi's age.

How do I contact Anat Ashkenazi?

The corporate mailing address for Ms. Ashkenazi and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Anat Ashkenazi's contact information.

Has Anat Ashkenazi been buying or selling shares of Eli Lilly and Company?

Anat Ashkenazi has not been actively trading shares of Eli Lilly and Company over the course of the past ninety days. Learn More on Anat Ashkenazi's trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (SVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, insiders at the sold shares 31 times. They sold a total of 2,074,936 shares worth more than $21,628,352,978.48. The most recent insider tranaction occured on January, 31st when Major Shareholder Lilly Endowment Inc sold 78,573 shares worth more than $50,920,804.11. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 1/31/2024.

Anat Ashkenazi Insider Trading History at Eli Lilly and Company

See Full Table

Anat Ashkenazi Buying and Selling Activity at Eli Lilly and Company

This chart shows Ms. Anat Ashkenazi's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $733.51
Low: $721.00
High: $737.45

50 Day Range

MA: $761.79
Low: $724.87
High: $792.28

2 Week Range

Now: $733.51
Low: $380.77
High: $800.78

Volume

1,998,801 shs

Average Volume

3,021,320 shs

Market Capitalization

$696.95 billion

P/E Ratio

126.47

Dividend Yield

0.71%

Beta

0.34